February 26, 2014 | Israeli company Andromeda Biotech, which develops treatments for diabetes, will be acquired by an unnamed American pharmaceutical company for several million dollars. However, Clal Biotechnology Industries, the current owner of Andromeda, could receive hundreds of millions of dollars in future payments, providing Andromeda meets development, registration, and sales milestones.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023

Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023

Israel Opens Its First Satellite Observatory
February 02, 2023

Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments